comparemela.com

Latest Breaking News On - Improving global outcome - Page 1 : comparemela.com

Samoa Observer | METI s Column - Another harmful effect of

In our previous column, we presented evidence of the harmful effects of the excessive amount of protein that is usually part of the standard animal-based diet that most of our people now consume. In this column, we will focus on another harmful effect of an animal-based diet that typically includ.

Guideline Update: KDIGO 2024 Management of Lupus Nephritis Includes Belimumab for Triple Therapy

The update includes a recommended triple therapy with belimumab as a first line treatment for class III or IV lupus nephritis following the approvals of belimumab and voclosporin.

Genexine s Long-acting Anemia Treatment GX-E4 Phase 3 Clinical Trial Interim Result Is Presented at WCN2023, Confirmed Non-inferiority Compared to Mircera

SEOUL, South Korea (BUSINESS WIRE) A clinical-staged proprietary platform technology biotech company Genexine (KQ 095700, CEO Neil Warma) and its Asian regional partner, KG Bio unveiled the interim results of phase 3 clinical trial of GX-E4 (Efepoetin alfa), a candidate for CKD (Chronic Kidney Disease) induced ane.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.